Skip to main content
KOMIPHARM INTERNATIONAL CO., LTD. logo

KOMIPHARM INTERNATIONAL CO., LTD. — Investor Relations & Filings

Ticker · 041960 ISIN · KR7041960006 KO Manufacturing
Open in API
Filings indexed 326 across all filing types
Latest filing 2022-11-01 Regulatory Filings
Country KR South Korea
Listing KO 041960

About KOMIPHARM INTERNATIONAL CO., LTD.

https://komipharm.co.kr/en/

Komipharm International Co., Ltd. is a biopharmaceutical company engaged in the development, manufacturing, and sale of products for both animal and human health. Its Animal Health Division provides a portfolio of veterinary vaccines, pharmaceuticals, and disinfectants. The company's Pharmaceutical Division is dedicated to the research and development of novel therapeutic agents, with key research areas including anticancer drugs and treatments for cancer-related pain and autoimmune diseases. Leveraging extensive experience, the company focuses on intensive R&D to expand its presence in the global bio-industry.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(마약성진통제(아편유사제)를 복용중인 암환자에게 PAX-1(경구용)을 경구 투여하는 한국식약처(MFDS)임상2상 시험계획(IND) 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KRX) system, specifically a 'Major Management Matter' disclosure regarding the approval of a Phase 2 clinical trial (IND) for a drug candidate (PAX-1). Since this is a formal regulatory announcement of a material business event (clinical trial approval) that does not fit into specific categories like financial reports or shareholder meetings, it is classified as a general regulatory filing.
2022-11-01 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. It details the share transactions (purchases) made by a director/major shareholder (Yang Kyung-hoon) of Komipharm. This type of filing is specifically categorized as 'Director's Dealing' (DIRS) as it reports insider trading activities.
2022-10-31 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the shareholding status, changes in ownership, and purpose of holding (management influence) for the company Komipharm. This falls under the category of Major Shareholding Notification.
2022-10-21 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of a director/major shareholder (Yang Kyung-hoon) of Komicpharm. This type of filing is a standard regulatory requirement for insider trading and ownership reporting, which falls under the 'Director's Dealing' category.
2022-10-21 Korean
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding a 'Decision to Acquire Treasury Shares' (자기주식 취득 결정). This is a formal regulatory filing detailing the company's plan to buy back its own shares, which falls under the category of 'Transaction in Own Shares'.
2022-09-23 Korean
투자판단관련주요경영사항(마약성진통제(아편유사제)를 복용중인 암환자에게 PAX-1(경구용)을 경구 투여하는 한국식약처(MFDS) 임상2상 시험계획 재신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Major Management Matter' disclosure regarding a clinical trial application (Phase 2) for a drug (PAX-1). Since this is a formal regulatory announcement of a material business event (clinical trial status) and does not fit into specific categories like financial reports, dividends, or M&A, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate disclosures.
2022-09-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.